Related Experiment Video

Updated: Mar 20, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

The oncolytic virus ΔPK has multimodal anti-tumor activity

Laure Aurelian1, Dominique Bollino2, Aric Colunga2

  • 1Department of Microbiology and Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201, USA laurelian@som.umaryland.edu.

Pathogens and Disease
|June 1, 2016
PubMed

Insights

A novel oncolytic virus (OV), known as ΔPK, demonstrates potent anti-tumor activity by lysing cancer stem cells and reversing the immunosuppressive tumor microenvironment. This emerging cancer therapeutic shows promise with minimal adverse effects in early human trials.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Oncolytic viruses (OVs) are a promising cancer therapy with a favorable safety profile.
  • Clinical efficacy of OVs is limited by poor tumor penetration, cancer stem cell (CSC) survival, and an immunosuppressive tumor microenvironment.
  • Overcoming these limitations is crucial for advancing OV-based cancer treatments.

Purpose of the Study:

  • To develop and evaluate a novel oncolytic virus (ΔPK) with enhanced multimodal anti-tumor capabilities.
  • To assess ΔPK's efficacy in targeting cancer stem cells and modulating the tumor microenvironment.
  • To investigate ΔPK's impact on immune responses, including cytokine profiles and immune checkpoints.

Main Methods:

  • Development of a modified oncolytic virus (ΔPK) with enhanced anti-tumor properties.
  • In vitro testing in melanoma cell lines and in vivo studies using xenograft animal models.
  • Analysis of programmed cell death pathways, autophagy modulation, cytokine secretion profiles, and immune checkpoint expression (CTLA-4, MICA).
  • Evaluation of safety and immunomodulatory effects in human patients.

Main Results:

  • ΔPK exhibited potent anti-tumor activity in melanoma cell lines and xenograft models, linked to virus replication and induction of multiple cell death pathways.
  • ΔPK effectively lysed cancer stem cells via autophagy modulation.
  • ΔPK reversed the immunosuppressive tumor microenvironment by decreasing IL-10/IL-18 and increasing TNF-α, GM-CSF, IL-6, and IL-1β secretion.
  • ΔPK upregulated MICA and downregulated CTLA-4, enhancing cytotoxic NK and T cell activity.
  • ΔPK was well-tolerated in human patients and modulated the Th1/Th2 balance.

Conclusions:

  • The novel oncolytic virus ΔPK demonstrates significant multimodal anti-tumor activity.
  • ΔPK effectively targets cancer stem cells and reverses the immunosuppressive tumor microenvironment, offering a promising therapeutic strategy.
  • ΔPK's favorable safety profile and immunomodulatory effects warrant further investigation in diverse tumor types.
Keywords:
HSVMICAimmunogenic cell deathinflammatory cytokinesmelanomaoncolytic virotherapy

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.6K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

10.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
1